Tralokinumab plus topical corticosteroids for the treatment of moderate‐to‐severe atopic dermatitis: results from the double‐blind, randomized, multicentre, placebo‐controlled phase III ECZTRA 3 trial*

2020308 citationsJournal Articlehybrid Open Access

Authors

Tralokinumab 300 mg in combination with TCS as needed was effective and well tolerated in patients with moderate-to-severe AD.

Good health and well-being

Published in: British Journal of Dermatology

Volume 184, Issue 3, pp. 450-463

Field-Weighted Citation Impact: 25.77